Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.
Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer, president, Clinical Operations, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the integration of sacituzumab govitecan-hziy (Trodelvy) into the treatment landscape of metastatic triple-negative breast cancer (TNBC).
Antibody-drug conjugates (ADCs), such as sacituzumab govitecan, which targets the TROP-2 receptor and harbors a cytotoxic payload linked to SN-38, have demonstrated significant efficacy in patients with metastatic TNBC, Burris says. The FDA granted an accelerated approval to the ADC in April 2020 based on data from a phase 1/2 trial (NCT01631552) of sacituzumab govitecan in patients with metastatic TNBC. In April 2021, the FDA granted a regular approval to the agent based on confirmatory data from the randomized phase 3 ASCENT trial (NCT02574455), where sacituzumab govitecan outperformed physician’s choice of single-agent treatments in this patient population, Burris explains.
Moreover, the National Comprehensive Cancer Network guidelines include sacituzumab govitecan as a recommended treatment for patients with metastatic TNBC who have received 2 or more prior systemic therapies, at least 1 of them for metastatic disease, Burris adds. Overall, the ADC is quickly becoming a standard of care option early in the treatment of patients with metastatic TNBC, Burris concludes.